Bruker 9.4T/ 20cm BioSpec MR Scanner for Colorado Animal Imaging Shared Resources

项目摘要和摘要 科罗拉多大学动物影像共享资源(AISR)正在申请资金购买一台Bruker 9.4Tesla/20 cm BioSpec核磁共振扫描仪。主要用户将是18名调查人员(主要是NIH和国防部 来自科罗拉多大学安舒茨医学院(AMC)的资金)，还有5%-10%的未决申请 每个调查员的仪器时间。几个较小的用户将请求大约1-2%的仪器时间 每个用户。所有用户由总共21个有效和6个待定R01授权、几个R21、DOD、K-、U- 和P类奖项。所请求的扫描仪将成为科罗拉多州AISR的一部分，这基本上是 科罗拉多大学癌症中心作为主要机构技术核心的支持(UCCC，P30 CA046934-25)和科罗拉多州临床与翻译科学研究所(CCTSI，UL1TR001082)。 AISR最初是在S10共享赠款工具申请(PI：N)成功后于2006年获得资助的。 Serkova，PhD)被授予购买Bruker 4.7 T/16 cm PharmaScan，这是第一个小动物 科罗拉多州的成像系统。自2006年以来，最先进的动物扫描仪，先进的生理学基础 成像方案和新型造影剂/分子探针使临床前生物医学发生了革命性的变化 在安舒茨医学院的研究，允许癌症生物学的非侵入性可视化， 活体动物的生理学和新陈代谢基于现有的科学需求和强大的制度性 作为对AISR的承诺，目前的动物成像设备已经扩展到包括Xenogen IVIS200， 一台西门子Inveon microPET/CT和一台Mediso microSPECT/CT。自2006年成立以来，AISR 已被124个用户使用(其中超过45个是核磁共振用户)，联邦 为支持科罗拉多州基于成像的翻译科学而授予的赠款。专业知识的三个主要领域 出现了：(一)肿瘤学成像；(二)神经科学；和(三)分子成像，建立了各种 利用现有4.7特斯拉扫描仪的MR协议。拥有11年历史的4.7特斯拉PharmaScan提供了 可靠的解剖图像，空间分辨率在150微米范围内。然而，主要的限制是 的PharmaScan，除了它的高龄和即将停止对Bruker的支持外，还包括Low 场强、有限的射频线圈和硬件容量(低信噪比、有限的面内分辨率) 令人望而却步的高分辨率成像、光谱成像、高级快速成像技术和成像 新的对比机制。PharmaScan的灵敏度和图像质量不足以满足以下要求 今天的标准。因此，AISR正在寻求用新的9.4扩展现有老化的MR技术 Tesla BioSpec，这将是我们的用户在以下领域非常需要的：(I)高分辨率解剖 成像(&lt；75微米)；(Ii)EPI(快速粗体和功能磁共振)；和(Iii)代谢1H-MRS和波谱 成像。此外，使用相控阵线圈进行快速心脏成像也是可取的。其中一些限制可能 通过使用microCT(改进的空间分辨率)、microPET/SPECT(代谢和分子)来克服 成像)，但高场MRI的添加对于最先进的AISR是必不可少的。AISR团队已经 组建了一个由NIH资助的神经科学、肿瘤学和医学领域的主要研究人员组成的强大团队 分子成像是组装这一应用程序的驱动力。主用户和次用户 将由一支由高素质的转换成像科学家、物理学家和化学家组成的团队依次提供支持 为高分辨率、功能化、分子化和高能化的发展和应用搭建成功的平台 使用所需的9.4特斯拉·布鲁克生物规格的基于代谢磁共振的方案。

PROJECT SUMMARY AND ABSTRACT University of Colorado Animal Imaging Shared Resources (AISR) is applying for funds to purchase a Bruker 9.4 Tesla/ 20 cm BioSpec MRI scanner. The major users will be 18 investigators (with major NIH and DOD funds) from the University of Colorado Anschutz Medical Campus (AMC), with pending request for 5-10% of instrument time per investigator. Several minor users will be requesting an estimated 1-2% of instrument time per user. All users are supported by a total of 21 active and 6 pending R01 grants, several R21, DOD, K-, U- and P-type of awards. The requested scanner will become a part of the Colorado AISR which is substantially supported as a major Institutional Technology Core by the University of Colorado Cancer Center (UCCC, P30 CA046934-25) and the Colorado Clinical and Translational Sciences Institute (CCTSI, UL1TR001082). The AISR was initially funded in 2006, after a successful S10 shared grant instrumentation application (PI: N. Serkova, PhD) was awarded to purchase a Bruker 4.7 T/16 cm PharmaScan, which was the first small animal imaging system in Colorado. Since 2006, state-of-the-art animal scanners, advanced physiology-based imaging protocols and novel contrast agents/ molecular probes have revolutionized pre-clinical biomedical research at the Anschutz Medical Campus, allowing for non-invasive visualization of cancer biology, physiology and metabolism in a living animal. Based on the existing scientific demand and strong institutional commitment to the AISR, the present animal imaging equipment has expanded to include a Xenogen IVIS200, a Siemens Inveon microPET/CT, and a Mediso microSPECT/CT. Since it was established in 2006, the AISR has been utilized by 124 users (with over 45 of them being MRI-users), with an impressive number of federal grants awarded to support imaging-based translational science in Colorado. Three major areas of expertise have emerged: (i) oncologic imaging; (ii) neuroscience; and (iii) molecular imaging, with various established MR protocols utilizing the existing 4.7 Tesla scanner. The eleven-year old 4.7 Tesla PharmaScan provides reliable anatomical images with spatial resolution in the range of 150 microns. However, the major limitations of the PharmaScan, besides its advanced age and soon-to-be discontinued Bruker support, include the low field strength, limited RF coils and hardware capacities (low SNR, limited in-plane resolution) which are prohibitive for high-resolution imaging, spectroscopic imaging, advanced rapid imaging techniques and imaging of new contrast mechanisms. The sensitivity and image quality from the PharmaScan is not sufficient by today's standards. Therefore, the AISR is seeking to expand the existing aging MR technology with a new 9.4 Tesla BioSpec which will be highly desirable for our users in the areas of: (i) high-resolution anatomical imaging (<75 µm); (ii) EPI (fast BOLD and functional MRI); and (iii) metabolic 1H-MRS and spectroscopic imaging. In addition, fast cardiac imaging with phase-array coils are desirable. Some of these limitations can be overcome by use of microCT (improved spatial resolution), microPET/ SPECT(metabolic and molecular imaging), but the addition of high-field MRI is essential for a state-of-the-art AISR. The AISR team has assembled a strong group of NIH funded principal investigators in the areas of neuroscience, oncology and molecular imaging who are the driving force for assembling this application. The major and secondary users will be supported by a team of highly qualified translational imaging scientists, physicists, and chemists in order to form a successful platform for the development and application of high-resolution, functional, molecular and metabolic MR based protocols using the requested 9.4 Tesla Bruker BioSpec.